Search Videos and More
News
The Storied Career Of Clinical Physicist Dr. Charlie Ma: From Philadelphia To Cancer Centers Worldwide
Over more than two decades at Fox Chase Cancer Center, Chang Ming Charlie Ma, PhD, FAAPM, FASTRO, Professor, Director of Physics, and Vice Chair of Radiation Oncology, helped transform clinical physics from a behind-the-scenes discipline into a force that reshaped how radiation therapy is planned, calculated, and delivered.
News
Fox Chase Cancer Center at ASTRO 2026
We are pleased to highlight several Fox Chase–Temple sessions taking place at ASTRO 2026. Explore the sessions below as our faculty and residents share their work throughout the meeting — and be sure to visit us at Booth #1336 in the ASTRO Exhibit Hall.
News
Adaptive Radiation Boost for Rectal Cancer (ARBOR)
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.
News
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
News
U.S. News & World Report Recognizes Fox Chase Cancer Center Among Nation’s Best Hospitals for Cancer Care
U.S. News & World Report has ranked Fox Chase Cancer Center among the nation’s top hospitals for cancer care according to the publication’s 2026-27 Best Hospitals rankings.
News
It Takes a Community for a Winn Scholar to Build a Clinical Trial
“My past experiences with Teach for America in North Philadelphia were a prologue to what I am doing now,” said Austin Williams, MD, MSEd, FACS, a surgical oncologist specializing in breast cancer at Fox Chase Cancer Center and Associate Program Director of the Breast Oncology Fellowship at Fox Chase.
News
Inspiration for Patients and Peers
Meet the Fox Chase physicians and researchers bridging clinical care excellence with breakthroughs in research—bringing new ideas and new hope to peers, patients, and their families.
News
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial
This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control and cure rate. The outcome for this study will be assessed over the first 2-3 years following completion of the therapy to which the patient is randomized.
News
From Fellowship to Faculty: Building a Fox Chase Career
Arielle Weiss, MD, Assistant Professor, Department of Surgery, and Jason Conger, MD, Assistant Professor, Department of Surgery, both in the Division of Gynecologic Oncology, came to Fox Chase Cancer Center shaped by different experiences, but ultimately each found the “right fit” in choosing a gynecologic oncology fellowship at Fox Chase and later joining its faculty.
News
From Bench to Bedside to the Block: Dr. Robert A. Winn on Extending Fox Chase's Legacy of Cancer Discovery and Bringing It to the Community
As he begins his tenure at Fox Chase Cancer Center, Dr. Robert Winn brings a national reputation in cancer leadership, discovery, and equitable access - and a vision for science that reaches farther than the clinic.
News
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
News
Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced).